Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 3-4/2022

23.08.2021 | review

Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review

verfasst von: Prof. Dr. med. Uwe Wollina, Anca Chiriac, Hristina Kocic, André Koch, Piotr Brzezinski

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 3-4/2022

Einloggen, um Zugang zu erhalten

Summary

Vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV‑2) has become a major tool in the battle against the coronavirus disease 2019 (COVID-19) pandemic. Numerous products have been developed and more are to come. Vaccination success varies greatly between different countries. There are a number of different vaccine types, such as mRNA, DNA vaccines, adenovirus vector vaccines, and full-length spike protein nanoparticles with a special matrix. The different types may also cause a different spectrum of adverse events. With mass vaccination, post-marketing surveillance for product safety becomes increasingly important. In this review, we discuss possible hypersensitivity and cutaneous adverse events related to SARS-CoV‑2 vaccination—from local reactions like COVID arm to systemic and severe reactions like anaphylaxis. Vaccination may also induce or exacerbate preexisting disorders such as herpes zoster infection. This review should provide information to tailor, whenever possible, vaccination to patients’ needs. It is a contribution to patient safety as well. There is general consensus that the benefits of SARS-CoV‑2 vaccination currently outweigh the risks of possible adverse events.
Literatur
1.
Zurück zum Zitat Perez Perez GI, Talebi Bezmin Abadi A. Ongoing challenges faced in the global control of COVID-19 pandemic. Arch Med Res. 2020;51(6):574–6.CrossRef Perez Perez GI, Talebi Bezmin Abadi A. Ongoing challenges faced in the global control of COVID-19 pandemic. Arch Med Res. 2020;51(6):574–6.CrossRef
2.
Zurück zum Zitat Blumental S, Debré P. Challenges and issues of anti-SARS-CoV‑2 vaccines. Front Med (Lausanne). 2021;8:664179.CrossRef Blumental S, Debré P. Challenges and issues of anti-SARS-CoV‑2 vaccines. Front Med (Lausanne). 2021;8:664179.CrossRef
3.
Zurück zum Zitat Ring J, Jutel M, Papadopoulos N, et al. Provocative proposal for a revised nomenclature for allergy and other hypersensitivity diseases. Allergy. 2018;73(10):1939–40.CrossRef Ring J, Jutel M, Papadopoulos N, et al. Provocative proposal for a revised nomenclature for allergy and other hypersensitivity diseases. Allergy. 2018;73(10):1939–40.CrossRef
4.
Zurück zum Zitat Blumenthal KG, Robinson LB, Camargo CA Jr, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562–5.CrossRef Blumenthal KG, Robinson LB, Camargo CA Jr, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562–5.CrossRef
5.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRef Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15.CrossRef
6.
Zurück zum Zitat Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV‑2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRef Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV‑2 vaccine. N Engl J Med. 2021;384(5):403–16.CrossRef
9.
Zurück zum Zitat El-Shitany NA, Harakeh S, Badr-Eldin SM, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study. Int J Gen Med. 2021;14:1389–401.CrossRef El-Shitany NA, Harakeh S, Badr-Eldin SM, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: a retrospective cross-sectional study. Int J Gen Med. 2021;14:1389–401.CrossRef
12.
Zurück zum Zitat Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–88.CrossRef Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479–88.CrossRef
14.
Zurück zum Zitat Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97.CrossRef Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–97.CrossRef
18.
Zurück zum Zitat Fischer D, Vander Leek TK, Ellis AK, Kim H. Anaphylaxis. Allergy Asthma Clin Immunol. 2018;14(2):54.CrossRef Fischer D, Vander Leek TK, Ellis AK, Kim H. Anaphylaxis. Allergy Asthma Clin Immunol. 2018;14(2):54.CrossRef
19.
Zurück zum Zitat McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–78.CrossRef McNeil MM, Weintraub ES, Duffy J, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137(3):868–78.CrossRef
20.
Zurück zum Zitat Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—december 14, 2020–january 18, 2021. JAMA. 2021;325(11):1101–2.CrossRef Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—december 14, 2020–january 18, 2021. JAMA. 2021;325(11):1101–2.CrossRef
26.
Zurück zum Zitat Hatziantoniou S, Maltezou HC, Tsakris A, et al. Anaphylactic reactions to mRNA COVID-19 vaccines: a call for further study. Vaccine. 2021;39(19):2605–7.CrossRef Hatziantoniou S, Maltezou HC, Tsakris A, et al. Anaphylactic reactions to mRNA COVID-19 vaccines: a call for further study. Vaccine. 2021;39(19):2605–7.CrossRef
27.
Zurück zum Zitat Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of currently authorized COVID-19 vaccines. J Investig Allergol Clin Immunol. 2021;31(1):92–3.CrossRef Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of currently authorized COVID-19 vaccines. J Investig Allergol Clin Immunol. 2021;31(1):92–3.CrossRef
28.
Zurück zum Zitat Paoletti G, Racca F, Piona A, et al. Successful SARS-coV‑2 vaccine allergy risk-management: the experience of a large Italian university hospital. World Allergy Organ J. 2021;14(5):100541.CrossRef Paoletti G, Racca F, Piona A, et al. Successful SARS-coV‑2 vaccine allergy risk-management: the experience of a large Italian university hospital. World Allergy Organ J. 2021;14(5):100541.CrossRef
29.
Zurück zum Zitat Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423–37.CrossRef Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9(4):1423–37.CrossRef
30.
Zurück zum Zitat Stone BD. PEG skin testing for COVID-19 vaccine allergy. J Allergy Clin Immunol Pract. 2021;9(4):1765.CrossRef Stone BD. PEG skin testing for COVID-19 vaccine allergy. J Allergy Clin Immunol Pract. 2021;9(4):1765.CrossRef
32.
Zurück zum Zitat Ring J, Worm M, Wollenberg A, et al. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases—practical recommendations. A position statement of ETFAD with external experts. J Eur Acad Dermatol Venereol. 2021;35(6):e362–e5.PubMedPubMedCentral Ring J, Worm M, Wollenberg A, et al. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases—practical recommendations. A position statement of ETFAD with external experts. J Eur Acad Dermatol Venereol. 2021;35(6):e362–e5.PubMedPubMedCentral
34.
Zurück zum Zitat Gotkin RH, Gout U, Sattler S, et al. Global recommendations on COVID-19 vaccines and soft tissue filler reactions: a survey-based investigation in cooperation with the international society for Dermatologic and aesthetic surgery (ISDS). J Drugs Dermatol. 2021;20(4):374–8.CrossRef Gotkin RH, Gout U, Sattler S, et al. Global recommendations on COVID-19 vaccines and soft tissue filler reactions: a survey-based investigation in cooperation with the international society for Dermatologic and aesthetic surgery (ISDS). J Drugs Dermatol. 2021;20(4):374–8.CrossRef
36.
Zurück zum Zitat Jedlowski PM, Jedlowski MF. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine. Dermatol Online J. 2021;27(1):13030/qt4xs486zg.CrossRef Jedlowski PM, Jedlowski MF. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine. Dermatol Online J. 2021;27(1):13030/qt4xs486zg.CrossRef
37.
Zurück zum Zitat Wollina U, Karadağ AS, Rowland-Payne C, et al. Cutaneous signs in COVID-19 patients: a review. Dermatol Ther. 2020;33(5):e13549.PubMed Wollina U, Karadağ AS, Rowland-Payne C, et al. Cutaneous signs in COVID-19 patients: a review. Dermatol Ther. 2020;33(5):e13549.PubMed
39.
Zurück zum Zitat Rodríguez-Jiménez P, Chicharro P, Cabrera LM, et al. Varicella-zoster virus reactivation after SARS-CoV‑2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021;12:58–9.CrossRef Rodríguez-Jiménez P, Chicharro P, Cabrera LM, et al. Varicella-zoster virus reactivation after SARS-CoV‑2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep. 2021;12:58–9.CrossRef
42.
Zurück zum Zitat Brzezinski P, Wollina U. HSV infections during the COVID-19 pandemic. Our Dermatol Online. 2020;11(2):19–20.CrossRef Brzezinski P, Wollina U. HSV infections during the COVID-19 pandemic. Our Dermatol Online. 2020;11(2):19–20.CrossRef
43.
Zurück zum Zitat Lopatynsky-Reyes EZ, Acosta-Lazo H, Ulloa-Gutierrez R, et al. BCG Scar local skin inflammation as a novel reaction following mRNA COVID-19 vaccines in two international healthcare workers. Cureus. 2021;13(4):e14453.PubMedPubMedCentral Lopatynsky-Reyes EZ, Acosta-Lazo H, Ulloa-Gutierrez R, et al. BCG Scar local skin inflammation as a novel reaction following mRNA COVID-19 vaccines in two international healthcare workers. Cureus. 2021;13(4):e14453.PubMedPubMedCentral
44.
Zurück zum Zitat Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626–39.CrossRef Forni G, Mantovani A, COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28(2):626–39.CrossRef
Metadaten
Titel
Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination—a narrative review
verfasst von
Prof. Dr. med. Uwe Wollina
Anca Chiriac
Hristina Kocic
André Koch
Piotr Brzezinski
Publikationsdatum
23.08.2021
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 3-4/2022
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-021-00876-0

Weitere Artikel der Ausgabe 3-4/2022

Wiener Medizinische Wochenschrift 3-4/2022 Zur Ausgabe